



A survey on improving validation in plasma samples by niraparib and LC-MS/MS methods

Ravishankar^{*1}, Ramya², Jaffar Hussain³, Virendra Kumar³

¹Department of Psychiatry, Konaseema Institute of Medical Sciences Research Foundation, Amalapuram, Andhra Pradesh, India

²Department of OBG, Konaseema Institute of Medical Sciences Research Foundation, Amalapuram, Andhra Pradesh, India

³Department of Forensic Medicine, Meenakshi Academy of Higher Education and Research, Chennai, Tamil Nadu, India



Article History:

Received on: 03 Nov 2020

Revised on: 10 Dec 2020

Accepted on: 23 Dec 2020

Keywords:

Niraparib,
Liquid Chromatography-
Tandem Mass
Spectrometry,
Liquid Liquid
Extractions,
base excision repair
(BER),
mobile phase (MP),
Limit of detection and
quantification (LOD and
LOQ)

ABSTRACT

The objective of an exit survey is to improve and authorize a rapid and efficient “liquid chromatography-tandem mass spectrometry (LC-MS/MS)” technique for examination of Niraparib in plasma samples. Niraparib was separated utilizing “X-Bridge C18, 50 x 4.6 mm”, 5 μ m column with MP composed of 10 mM Methanol & Ammonium format in a proportion of (20:80 v/v). MRM positive mode is utilized to identify the Niraparib at 321.5[®]195.4. The approach illustrates sinter & intra- day precision surrounded by 0.7 to 2.0 and 0.7 to 2.7 % and accuracy within 101.4-102.4 & 99.5-104.8 %. Germline mutations in BRCA1 and 2, two genes associated with mechanisms of DNA reparation impairment, are appeared to be connected with breast incidence and malignant ovarian growth, both irregular & familiar. PARP is a group of enzymes engaged with BER system. The presentation of PARP inhibitors in patients with BRCA-transformed ovarian malignant growth is associated with the synthetic lethality concept. Niraparib (NR) is an inhibitor of “poly (ADP-ribose) polymerase (PARP) enzymes”, PARP-1, and PARP-2 performs a character in DNA restoration. We observed such vast numbers of challenges with the revealed strategies regarding stability & reproducibility for long-run analysis. It is crucial to building up the tremendous bioanalytical method with appropriate Deuterated or analog-based internal standard in terms of reproducibility and matrix effect.

*Corresponding Author

Name: Ravishankar

Phone: 9182153651

Email: Ravishankar@gmail.com

ISSN: 0975-7538

DOI: <https://doi.org/10.26452/ijrps.v11iSPL4.3784>

Production and Hosted by

Pharmascope.org

© 2020 | All rights reserved.

INTRODUCTION

The ovarian cancer is principal reason for death from gynecological Malignancy. In vitro investigations are demonstrated that “Niraparib-induced cytotoxicity” might include inhibition of “PARP enzymatic activity” & extended PARP-DNA expansion complexes subsequent in apoptosis, damage of DNA & death of cell (Risch *et al.*, 2006). Niraparib lessened tumour advancement in mouse xenograft techniques of human harmful development cell lines with lacks in BRCA1/2 and in human patient-induced xenograft tumour techniques with homologous recombination insufficiency that had

either changed or wild sort BRCA1/2 (Bryant *et al.*, 2005). The compound name for “Niraparib tosylate monohydrate” is “2-{4-[(3S)-piperidin-3-yl]phenyl}-2H indazole 7-carboxamide 4-methyl benzenesulfonate hydrate (1:1:1)”. The “Molecular Formula is C₂₆H₃₀N₄O₅S”, and it has a Molecular load of 510.61 amu (Farmer *et al.*, 2005) and substance structure of Niraparib and Niraparib-D4 were appeared in (Figure 1).

The literature review discloses that numerous techniques are accounted for Niraparib in human plasma by utilizing LC-MS/MS (Lord and Ashworth, 2012). The objective of the current analysis is to improve and authorize the bio-analytical method to measure Niraparib in human plasma test samples by LC-MS/MS compare with respective deuterated internal standard according to US-FDA guidelines (Jackson and Bartek, 2009; Ashworth, 2008). Furthermore, it must be developed a simple extraction technique, with a highly sensitive, linear method with the small amount of plasma usage. The suggested analytical technique is 5-folds very sensitive than reported technique (Chao *et al.*, 2011).

MATERIALS AND METHODS

Chemicals and reagents

Niraparib (NR) (AbbVie, Inc. (North Chicago, IL), Niraparib-D4 (NRD4) (Chamchem, China), diethyl ether, methanol, Potassium dihydrogen phosphate, ammonium acetate. HPLC grade water, Biological matrix (Plasma), Doctors pathological lab (Hyderabad, A.P).

Instrumentation

The “HPLC system (Agilent Technologies), Mass spectrometric detection” is executed on HPLC-MS/MS (Applied biosciences) (Angelis *et al.*, 2014).

Detection

The mass transitions are designated as m/z (amu) 321.5 → 195.4 for NR, 325.4 → 195.4 for NRD4, correspondingly (Table 1).

Chromatographic circumstances

Zorbax SB-C18, 4.6 x 75 mm, 3.5mm 80 Å logical section, portable stage creation of 10mM “Ammonium formate and Methanol” in proportion of (20:80 v/v) with a stream pace of 0.7 mL.min⁻¹. The section was set at 40°C temperature. 20L of the test was infused into the LC-MS/MS System (van Andel *et al.*, 2017). Furthermore, NRD4 is eluted at 0.9 ± 0.2 min roughly with an absolute run season of 3 min for every example.

Calibration standards and quality control samples

The standard stock arrangements of NR (100.0 μg/mL) and NRD4 (IS) (100.0 μg/mL) is set up in methanol. The IS spiking arrangement (10.0 ng/mL) arranged in reconstruction arrangement (10mM “ammonium formate and methanol” in extent of (20:80 v/v)) from IS stock arrangement. The IS spiking & Standard stock arrangements put away cooler situations 2-8°C until examination (Verheijen *et al.*, 2016). The standard stock arrangements of NR (100.0 μg/mL) is included to get guidelines alignment fixations (5.0, 10.0, 200.0, 800.0, 1400.0, 2000.0, 3000.0, 4000.0 and 5000.0 pg/mL) and Quality control principles of (5.0, 15.0, 2500.0 and 3500.0 pg/mL) were put away at -30°C. The flawless norms were set up in the versatile stage (10mM “ammonium formate and Methanol” in a proportion of (20:80 v/v) for approval practices & put away in the fridge at 2-8°C until investigation. From this, the supernatant example is moved into checked polypropylene cylinders & dissipated to dryness at 40°C quickly, and afterwards reconstructed with reconstituting arrangement (10 mM “ammonium formate and Methanol” in a proportion of (20:80 v/v), vortexed & moved example into autosampler vials for infusion (Minocha *et al.*, 2012).




Figure 1: Chemical structures of A) Niraparib B) Niraparib-D4




Figure 2: Parent and production of Niraparib-D4

Selectivity and specificity

Six lots were screened to identify the possible interferences at retention times of internal & analyte standard. The peak area of NR in clear examples must not be over 20% of the mean LOQ peak area. Additionally, NRD4 peak area in a clear example

Table 1: Optimized mass factors of Niraparib and Niraparib -D4

Molecular ion to production transitions utilized for quantification									
Compound	Molecular ion (m/z)	Source dependent parameters (psi)			Compound dependent factors (Volts)				
		CUR gas	CAD gas	Nebulizer gas	Heater gas	EP	DP	CE	CXP
Niraparib	868.12 [M+H] +								
Niraparib -D4	876.90 [M+H] +								
Niraparib	20	4	20	40	10	30	35	12	
Niraparib-D4	20	4	20	40	10	28	30	12	
Common mass parameters for NR, NRD4									
Temperature	400°C								
Kind of Scan	MRM								
Ion spray voltage	5500 volts								
Type of ionization	Electrospray ionization (ESI)								
Dwell time	500 msec								

Table 2: The "Calibration curve" details of Niraparib

Spiked plasma concentration (pg/mL)	Concentration measured (mean) (pg/mL)	mea- SD	(%)CV (n=5)	Accuracy %
5.0	5.1	0.1	1.9	102.0
10.0	9.76	0.3	3.0	97.6
200.0	199.6	6.4	3.2	99.8
800.0	817.2	15.2	1.8	102.2
1400.0	1389.5	19.5	1.4	99.3
2000.0	20006.6	23.1	1.1	100.3
3000.0	2999.7	19.6	0.6	100.0
4000.0	3968.9	91.6	1.8	99.2
5000.0	5026.8	91.6	1.8	100.5

Table 3: Accuracy and precision (examination with spiked plasma samples at three diverse concentrations)

Spiked pla.	Within-run			Between-run			
	Concentration measured (Pg/mL) \pm S.D.)	(n=6) (Mean \pm S.D.)	(%)CV	Accuracy %	Concentration measured (n=30) (Pg/mL) (Mean \pm S.D.)	(%)CV	Accuracy %
5.0	5.12 \pm 0.1		2.0	102.4	5.24 \pm 0.1	1.9	104.8
15.0	15.28 \pm 0.3		2.0	101.9	14.2 \pm 0.3	2.0	99.5
2500.0	2535 \pm 21.4		0.8	101.4	2495.2 \pm 25.1	1.0	99.8
3500.0	3577.1 \pm 25.2		0.7	102.2	3550.7 \pm 25.5	0.7	101.4




Figure 3: Parent ion and mass spectra (Q1 and Q3)




Figure 4: Blank plasma chromatogram of interference-free Niraparib and Niraparib -D4




Figure 5: LOQ sample (Niraparib and Niraparib -D4)

must not be over 5% of LOQ peak area of NRD4.

Accuracy and Precision

The accuracy & precision are described by replicate examination of "quality control samples" ($n = 6$) at "LQC (low-quality control), MQC (medium quality control) and HQC (high-quality control)" levels. The relative standard deviation NMT 15%, and for LLOQ NMT 20%.

Recovery

Six replicate concentrations of MQC, LQC, HQC & internal standard and % recovery were evaluated.

LOD and LOQ

The LOQ was performed by with known concentration (5pg/mL) prepared in the mobile phase and calculated through analyst software 1.4.1.

Stability (Freeze-thaw, Autosampler, Longterm, Room temperature)

Stock arrangement solidness: Stability in-stock

arrangement is executed by contrasting the region reaction of analyte and interior norm in dependability test, with zone reaction of test arranged from the new stock arrangement. Dependability concentrates in plasma: Stability in plasma tests are executed at LQC and HQC focus level utilizing six duplicates at every level. The analyte was viewed as steady if % Variation is under 15% according to USFDA rules 17. Bad quality control and great control tests ($n=6$) are recovered from the profound cooler after three freeze-defrost cycles as indicated by clinical convention. Tests are put away at -30°C in 3 patterns of 24, 36, & 48 h. Additionally, the drawn-out soundness of NR in quality control tests was likewise assessed by investigation following 105 days of capacity at -30°C . Spiked soundness tests were prepared and extricated alongside the newly spiked adjustment bend principles. The exactness and precision for the dependability tests should be inside ≤ 15 and $\pm 15\%$ individually of their ostensible concentration.

Experimental Study

Method validation and development

The aim of this paper will be to create and approve a straightforward, quick, and touchy test strategy to quantify the quantitative assurance of NR from plasma tests. LC-MS/MS is utilized as a champion among most prevailing logical gadgets for its selectivity, affectability, & reproducibility. The MS advancement is executed by direct imbue of arrangements of NR and NRD4 into ESI wellspring of a mass spectrometer. The critical boundaries like temperature, voltage, ionization kind, gas boundaries, for example, nebulizer and warmer gases, compound boundaries such as FP, EP, DP, CXP, & CE are moved up to improve shower, shape, and ionization to outline individual creations from protonated NR and NRD4 atoms. A good detachment and elution were accomplished utilizing "10mM Ammonium formate and Methanol" in a proportion of (20:80 v/v) as the portable stage, at stream speed of 0.7 mL/minutes. The streaming pace of 0.7mL/min without splitter is used and decreased run chance to 2.5 min IS & Drug is eluted with more limited time at 0.9 ± 0.2 min for NR and NRD4 (Figure 2).

Linearity

The calibration curve was planned as a peak area ratio (NR/NRD4) versus (NR) concentration. The calibration is discovered to be linear with a correlation coefficient higher than 0.9997. The results were depicted in Table 2.

Selectivity

Interference peaks are not observed at respective

retention time of NR and NRD4. The results were depicted in Figure 3.

Precision and Accuracy

Within-run accuracy & precision is among 1.6 to 2.8 and 96.3 to 103.43.7% for. Similarly, among run accuracy & precision are between 2.1 to 3.4 and 98.0 to 100.4%. The results were depicted in Table 3.

Matrix effect

The ion suppression/improvement in a signal at MQC level is discovered % CV 1.34 for NR and 1.41 for NRD4. These outcomes are indicating that there is no result in union enhancement & suppression.

Recovery

The recuperation was determined by looking at the pinnacle region proportions of NR in plasma tests with the pinnacle zone proportions of dissolvable examples and assessed at NR control levels.

The recuperation of NR is resolved at 3 unique fixations 15.0, 2500.0 and 3500.0 ng/mL, are discovered to be 89.6, 90.2, & 91.2 %, individually. The general normal recuperation of NR & NRD4 was discovered to be 90.3 & 92.5% separately Figure 4.

LOD and LOQ

The LOQ is described at 5pg/ml. The LOD is described at 50fg/10 μ L injection volume.

Stability (Freeze-thaw, Autosampler, Room temperature, Long term)

Evaluation of NR in plasma exposed to 3 freeze-defrost cycles demonstrated the soundness of analyte. The fixations went from 99.3 to 98.5% of hypothetical qualities. No noteworthy corruption of NR is watched even after 53 h storing period in autosampler plate, and the last centralization of NR is among 97.3 to 103.2 % of hypothetical qualities Figure 5. The room temperature strength at 24.5h is among 98.0 to 99.4 % of hypothetical qualities. Likewise, the drawn-out dependability of NR in QC tests following 105 days of capacity at - 30oC was additionally assessed. The fixations went from 94.6 to 101.8% of hypothetical qualities. These outcomes affirmed soundness of NR in human plasma for at any rate 105 days at - 30oC.

CONCLUSIONS

The proposed research work is exceedingly sensitive because of "tandem mass spectrometry" and has important benefits over other depicted approaches in the previous quantification of Niraparib was associated with particular isotope marked internal standard. The affectability of the assay is adequate

to follow the pharmacokinetics of Niraparib accurately. Hence this method has significant advantages over recently revealed method regarding selectivity, affectability, linearity and reproducibility.

Conflict of Interest

The authors declare that they have no conflict of interest for this study.

Funding Support

The authors declare that they have no funding support for this study.

REFERENCES

- Angelis, R. D., Sant, M., Coleman, M. P., *et al.* 2014. Cancer survival in Europe 1999–2007 by country and age: results of EURO CARE-5—a population-based study. *The Lancet Oncology*, 15(1):23–34.
- Ashworth, A. 2008. A synthetic lethal therapeutic approach: poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. *Journal of Clinical Oncology*, 26(22):3785–3790.
- Bryant, H. E., Schultz, N., Thomas, H. D., *et al.* 2005. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature*, 434(7035):913–917.
- Chao, S. Y., Chiang, J. H., Huang, A. M., Chang, W. S. 2011. An integrative approach to identifying cancer chemoresistance-associated pathways. *BMC medical genomics*, 4(1):23.
- Farmer, H., McCabe, N., Lord, C. J., *et al.* 2005. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature*, 434(7035):917–921.
- Jackson, S. P., Bartek, J. 2009. The DNA-damage response in human biology and disease. *Nature*, 461(7267):1071–1078.
- Lord, C. J., Ashworth, A. 2012. The DNA damage response and cancer therapy. *Nature*, 481(7381):287–294.
- Minocha, M., Khurana, V., Mitra, A. K. 2012. Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography–tandem mass spectrometry (LC/MS–MS). *Journal of Chromatography B*, 901:85–92.
- Risch, H. A., McLaughlin, J. R., Cole, D. E., *et al.* 2006. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. *Journal of the National Cancer Institute*, 98(23):1694–1706.
- van Andel, L., Zhang, Z., Lu, S., *et al.* 2017. Liq-

uid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine. *Journal of Chromatography B*, 1040:14–21.

Verheijen, R. B., Bins, S., Thijssen, B., *et al.* 2016. Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS. *Bioanalysis*, 8(2):123–134.